IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

TY - JOUR

T1 - IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

AU - Humbert, Marc

AU - Bousquet, Jean

AU - Bachert, Claus

AU - Palomares, Oscar

AU - Pfister, Pascal

AU - Kottakis, Ioannis

AU - Jaumont, Xavier

AU - Thomsen, Simon Francis

AU - Papadopoulos, Nikolaos G.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

AB - Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

KW - Omalizumab

KW - Asthma

KW - Multimorbidities

KW - Treatment

KW - Allergic rhinitis

KW - Rhinoconjunctivitis

KW - Chronic rhinosinusitis with nasal polyps

KW - Vernal keratoconjunctivitis

KW - Food allergies

KW - Allergic bronchopulmonary aspergillosis

U2 - 10.1016/j.jaip.2019.02.030

DO - 10.1016/j.jaip.2019.02.030

M3 - Review

C2 - 30928481

SN - 2213-2198

VL - 7

SP - 1418

EP - 1429

JO - The Journal of Allergy and Clinical Immunology: In Practice

JF - The Journal of Allergy and Clinical Immunology: In Practice

IS - 5

ER -